Placental site trophoblastic tumour (PSTT) differs from choriocarcinoma in which key characteristic?
- A PSTT produces predominantly hPL rather than markedly elevated hCG ✓
- B PSTT responds well to EMA-CO chemotherapy
- C PSTT always follows a complete hydatidiform mole
- D PSTT has higher metastatic potential than choriocarcinoma
Correct answer: A. PSTT produces predominantly hPL rather than markedly elevated hCG
Explanation
Placental site trophoblastic tumour arises from intermediate trophoblast and characteristically produces human placental lactogen (hPL) rather than high levels of hCG — hCG is only modestly elevated. This makes hCG monitoring less reliable for PSTT surveillance. PSTT is relatively resistant to EMA-CO; hysterectomy is the mainstay of treatment for localised disease. It can follow any pregnancy type, not only molar pregnancies.
Reference: Williams Obstetrics, 26th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.